FES: Effect on Walking in the Real World and Participation in Daily Life in People With Multiple Sclerosis.
Part of paid clinical trials in San Francisco, California.
- Sponsor
- University of California, San Francisco
- Study ID
- NCT07706114
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Impaired Gait
- Multiple Sclerosis
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Use of functional electrical stimulation for extended duration on the participants' weaker limb — DEVICEParticipants will be randomized into two groups. Group 1: will receive FES during EPOCH A (4 months) and EPOCH B (4 months). Group 2 (delayed start): will receive 4 months of Sham stimulation during EPOCH A, and FES during EPOCH B. Follow-up: After Epoch B, all participants will be followed for 1 month with no FES sleeve or stimulation to assess carryover.
Study Details
Multiple sclerosis (MS) is a chronic, neurodegenerative disease and the most common cause of non- traumatic disability in young adults. Foot drop, arising from MS-induced muscle weakness, leads to impaired mobility, increased fall risk, reduced overall physical activity and reduced health-related quality of life. Functional electrical stimulation (FES) represents a revolutionary approach for addressing gait mobility challenges in MS and evolution in the technology has greatly improved its design, comfort, and functionality. Despite its proven benefits, FES is underutilized in MS clinical practice and lacks a comprehensive assessment of its long-term effectiveness and impact in real-world applications. Study objectives are to evaluate the utility of FES for improving function and real-world outcomes in people with MS (PwMS) who have gait impairments. Study design: 4-month randomized controlled trial (RCT) (n=70 PwMS) evaluating FES efficacy. Group 1: 4M FES; Group 2: 4M sham stimulation, followed by both groups: 4M FES, then 1M (no-FES) follow-up assessing carryover. We will assess gait quality, muscle function, physical activity, and FES adoption factors, with covariates including age, sex, MS severity, MS symptoms, biomechanical factors, and device usage patterns.
Key Dates
- First listed
- Jul 15, 2026
- Start date
- Aug 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Jul 2, 2029
- Completion
- Oct 30, 2030
Study Design
- Enrollment
- 70 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Sham Comparator: Group 2: FES ShamThis group will receive 4 months of sham stimulation followed by 4 months of functional electrical stimulation.
- Active Comparator: Group 1: FES FullThis group will receive 8 months of functional electrical stimulation.
Primary Outcome Measure
Adherence [ Time Frame: 4 months ]
Central Contacts
- Valerie J Block, DPTSc415-502-7208
- Jeannine Bradsby415-353-4612
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California San Francisco, Weill Institute for Neurosciences | San Francisco | California | 94158 | Valerie J Block, PT, DPTSc (PRINCIPAL_INVESTIGATOR) |
Find similar trials in San Francisco, CA
Related Studies
- Serum Auto-Antibodies in Neurological DiseasesEnrolling By Invitation · University of California, Davis · Sacramento, California
- ECoG BMI for Motor and Speech ControlRecruiting · Karunesh Ganguly · San Francisco, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Entire-body PET Scans for Multiple SclerosisEARLY_PHASE1 · Recruiting · Brain Health Alliance · Ladera Ranch, California